Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting
- Conditions
- HIV InfectionsStreptococcus Pneumoniae
- Interventions
- Biological: pneumococcal conjugate vaccineBiological: pneumococcal polysaccharide vaccine
- Registration Number
- NCT00622843
- Brief Summary
Purpose: To study the immune response of the newly licensed pneumococcal conjugate vaccine (PCV) in comparison to the pneumococcal polysaccharide vaccine (PPV) to determine if a significantly better immunologic response to boosting can be elicited in patients previously vaccinated with PPV.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 275
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Group 1 pneumococcal conjugate vaccine PCV, 210 patients Group 2 pneumococcal polysaccharide vaccine PPV, 110 patients Group 3 pneumococcal polysaccharide vaccine PPV, HIV-negative, 25 patients
- Primary Outcome Measures
Name Time Method The measure of PPV and PCV efficacy will be assessed by the level of serotype-specific antibody levels, measured by ELISA. Day 180 after vaccination
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (6)
Tripler Army Medical Center
🇺🇸Tripler AMC, Hawaii, United States
Naval Medical Center San Diego
🇺🇸San Diego, California, United States
Walter Reed Army Medical Center
🇺🇸Washington, District of Columbia, United States
San Antonio Military Medical Center
🇺🇸Lackland AFB, Texas, United States
Naval Medical Center Portsmouth
🇺🇸Portsmouth, Virginia, United States
National Naval Medical Center
🇺🇸Bethesda, Maryland, United States